Price History
Apr 8, 2026 — Aug 3, 2026Investment Snapshot
- P/B of 43.96 — trading above book value
- Piotroski F-Score 2/9 — signs of financial weakness
- Loss-making — negative ROE of -361.1%
Polaryx Therapeutics, Inc. - Common Stock (PLYX) is a Healthcare company operating in Biotechnology, listed on the NASDAQ , with a market capitalisation of $109 million . Key value metrics: P/B ratio 43.96, Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Polaryx Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, PLYX shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and negative return on equity of -361.1% (sector average: -20.1%).
StockPik's composite Value Score for PLYX is 25/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
PLYX shows earnings growing at 70%.